CRP and sclerosing cholangitis: Five other cases (cases 2, 3, 23, 25, 32; Table 2) avoided ERCP, but those presenting with comorbidities affecting the biliary duct (e.g., sclerosing cholangitis, cases 3, 23, 25) were followed-up by abdominal ultrasound and/or MRI and biology tests according to the ACG guidelines 2015; the two patients who underwent EUS for pancreatitis in absence of other pancreatobiliary comorbidities were followed-up clinically and with biology tests at 6 and 12 months, including complete hepatic function tests, CRP and lipase, documenting a complete normalization of both clinic and biology.